3,3′-Diindolylmethane and Paclitaxel Act Synergistically to Promote Apoptosis in HER2/Neu Human Breast Cancer Cells

Journal of Surgical Research

Volumn 132, Issue 2, 2006, Pages 208-213

  McGuire, K P ^a   Ngoubilly, N ^a   Neavyn, M ^a   Lanza Jacoby, S ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

3,3 diindolylmethane; apoptosis; breast cancer; HER2 neu; paclitaxel

Indexed keywords

3,3' DIINDOLYLMETHANE; 3,3'-DIINDOLYLMETHANE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PACLITAXEL;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL DIVISION; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DRUG SYNERGISM; FEMALE; HUMANS; INDOLES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PACLITAXEL; PHOSPHORYLATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 33646088121     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2006.02.008     Document Type: Article

References (33)

1. Slamon D.J., Godopphin W., Jones L.A., et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707
2. Gusterson B.A., Gelber R.D., Goldhirsch A., et al., International Breast Cancer Study Group. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10 (1992) 1049
3. Jarvinen T.A., Holli K., Kuukasjarvi T., et al. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77 (1998) 2267
4. Yu D., Liu B., Tan M.J., et al. Overexpression of cErbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1 independent mechanisms. Oncogene 13 (1996) 1359
5. Yu D., Liu B., Jing T., et al. Overexpression of p185cErbB2 and p170mdr-1 renders breast cancer cells highly resistant to paclitaxel. Oncogene 16 (1998) 2087
6. Kubota T., Uemura Y., Kobayashi M., and Taguchi H. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res 23 (2003) 4039
7. Chinni S.R., Li Y., Upadhyay S., et al. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 20 (2001) 2927
8. Bell M.C., Crowley-Nowick P., Bradlow H.L., et al. Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol 78 (2000) 123
9. Bradlow H.L., Michnovicz J., Telang N.T., et al. Effects of dietary indole-3-carbinol on estradiol metabolism and spontaneous mammary tumors in mice. Carcinogenesis 12 (1991) 1571
10. Nachshon-Kedmi M., Fares F.A., and Yannai S. Therapeutic activity of 3,3′-diindolylmethane on prostate cancer in an in vivo model. The Prostate 61 (2004) 153
11. Tiwari R.K., Guo L., Bradlow H.L., et al. Selective response of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 86 (1994) 126
12. Cover C.M., Hsieh S.J., Tran S.H., et al. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273 (1998) 3838
13. Telang N.T., Katdare M., Bradloe H.L., et al. Inhibition of proliferation and modulation of estradiol metabolism. Novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med 216 (1997) 246
14. Cover C.M., Hsieh S.J., Cram E.J., et al. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Res 59 (1999) 1244
15. Hong C., Kim H.A., Firestone G.L., and Bjeldanes L.F. 3,3′- Diindolylmethane (DIM) induces a G1 cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21 WAF1/CIP1 expression. Carcinogenesis 23 (2002) 1297
16. Ge X., Yannai S., Rennert G., et al. 3,3′-Diindolylmethane induces apoptosis in human cancer cells. Biochem Biophys Res Commun 228 (1996) 153
17. Rahman K.M., Aranha O., Glazyrin A., Chinni S., and Sarkar F. Translocation of Bax to mitochondria induces apoptotic cell death in Indole-3-carbinol treated breast cancer cells. Oncogene 19 (2000) 5764
18. Howells L.M., Gallacher-Horley B., Houghton C.E., Manson M.M., and Hudson E.A. Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. Mol Cancer Ther 1 (2002) 1161
19. Rahman Li Y., and Sarkar F.H. Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr Cancer 48 (2004) 84
20. Rahman Li Y., and Sarkar F.H. Inhibition of nuclear translocation of nuclear factor-kappaB contributes to 3,3′-diindolylmethane-induced apoptosis in breast cancer cells. Cancer Res 65 (2005) 364
21. Gusterson B.A., Gelber R.D., Goldhirsch A., et al., International Breast Cancer Study Group. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol 10 (1992) 1049
22. Jarvinen T.A., Holli K., Kuukasjarvi T., et al. Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 77 (1998) 2267
23. Yu D., Liu B., Tan M.J., et al. Overexpression of cErbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1 independent mechanisms. Oncogene 13 (1996) 1359
24. Yu D., Liu B., Jing T., et al. Overexpression of p185cErbB2 and p170mdr-1 renders breast cancer cells highly resistant to paclitaxel. Oncogene 16 (1998) 2087
25. Hong C., Firestone G.L., and Bjeldanes L.F. Bcl-2 family-mediated apoptotic effects of 3,3′-diindolylmethane (DIM) in human breast cancer cells. Biochem Pharmacol 63 (2002) 1085
26. Merlin J.L., Barberi-Heyob M., and Bachmann N. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel. Ann Oncol 13 (2002) 1743
27. Lee S., Yang W., Lan K.H., et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62 (2002) 5703
28. Schimmel K.J., Richel D.J., van den Brink R.B., and Guchelaar H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev 30 (2004) 181
29. Sarkar F.H., and Li Y. Cell signaling pathways altered by natural chemopreventive agents. Mutat Res 555 (2004) 53
30. Chang X., Firestone G.L., and Bjeldanes L.F. Inhibition of growth factor-induced ras signaling in vascular endothelial cells and angiogenesis by 3,3′-diindolylmethane. Carcinogenesis (2005) 2301
31. Jacobs I.C., and Zeligs M.A. New formulation strategies for bioavailability enhancement of two poorly absorbed phytonutrient supplements. Diindolylmethane and yohimbine bark extract. Proc Int Sym Control Rel Bioact Mater 27 (2000) 1324
32. Klos K.S., Zhou X., Lee S., Zhang L., Yang W., Nagata Y., and Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98 (2003) 1377
33. Srivastava R.K., Srivastava A.R., Korsmeyer S.J., Nesterova M., Cho-Chung Y.S., and Longo D.L. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18 (1998) 3509